

Polpharma Biologics and the University of Warsaw have signed a cooperation agreement in an important step toward building the company's international scientific cooperation platform

Warsaw, August 26, 2020 - Polpharma Biologics, Poland's largest biotech developer and manufacturer of biosimilar and innovative biological drugs, and the Faculty of Biology of the University of Warsaw have initiated scientific and educational cooperation. The results of their first joint venture will be released in spring 2021. Following on its partnership with the Medical University of Gdańsk, Polpharma Biologics now begins close cooperation with the University of Warsaw and is also preparing to strengthen its relationships with a Dutch research center in the company's bid to establish an international scientific cooperation platform. Direct partnerships with universities and commitment to education exemplify Polpharma Biologics' investment in Poland's emerging biotechnology sector and transformation to teaching practical skills as a key element of education.

The University of Warsaw is a leader among Polish universities with biotechnology majors and offers a wide-ranging natural science program. As part of their education, students acquire the knowledge and skills to apply molecular and biotechnology techniques. Graduates are prepared to work in research, analytical and diagnostic laboratories, pharmaceutical companies and to perform research using biological material.

Polpharma Biologics is a biopharmaceutical company which develops and produces biosimilar pharmaceuticals and innovative biological drugs. It currently employs over 650 highly specialized researchers, scientists and engineers, has modern laboratories and production facilities for the development and production of biological drugs. Top international specialists (including over 50 Polish biotechnologists who have returned from abroad) manage operations and share knowledge from the world's leading biotechnology companies. Polpharma Biologics works closely with research centers, including the Medical University of Gdańsk, and as many as 10% of employees hold doctorate degrees.

"Talks on long-term cooperation between the University of Warsaw and Polpharma Biologics have been ongoing for many months. The university works with major companies, so we are glad to see the cooperation agreement with Polpharma Biologics, a leading Polish company that focuses on research it then implements in production. Our joint efforts will include dedicated training of highly specialized staff who will support Polpharma's research centers and cooperation on research projects. We also intend to jointly apply for funding to conduct ground-breaking research. For undergraduate and graduate students of the University of Warsaw, the agreement opens the way to internships and work in modern laboratories focused on applied research and the development of innovative products. I think the experiences of the ongoing pandemic clearly show how important it is to quickly translate scientific achievements into products that can help us all," said Prof. Marcin Patys, rector of the University of Warsaw.

"We are very pleased with signing of the contract with the University of Warsaw. Polpharma Biologics employs the best specialists from around the world, enabling the transfer of know-how and professional development in the biotechnology sector on an unprecedented scale in Poland. Last year

alone, we employed over 200 people, and by the end of 2020 we are recruiting another 270 people. We have been cooperating with the Medical University of Gdańsk for a long time. The contract establishing cooperation with the University of Warsaw is another step toward building a platform for the exchange of unique knowledge and experience. Biotechnology cannot be learned only from textbooks - the critical element is practical experience in the laboratory and on the production line, and no one in Poland knows this as well as we do. We consider sharing this knowledge, at the level of cooperation with research centers and through internship programs, an investment in the biotechnology sector in Poland, which is being built almost from scratch,” says Agnieszka Kosowska, General Counsel, Head of legal affairs and external relations at Polpharma Biologics.

The cooperation of Polpharma Biologics with the University of Warsaw is another step towards creating a common platform for the exchange of knowledge and experience between the world of science and business, as well as the development of a training method for biotechnology specialists in Poland and Europe. The first results of the cooperation will be available in spring 2021. The company has long been working closely with research centers, including with the Medical University of Gdańsk. It is also preparing to commence a cooperation with a Dutch research center near another Polpharma Biologics location. Polpharma Biologics is also developing the Career Laboratory internship program for graduates and students in the final years of biotechnology, biology, chemistry and related science programs.

Polpharma Biologics is a biopharmaceutical company which develops and produces biosimilar pharmaceuticals and innovative biological drugs. The Polpharma Biologics Group conducts research and development in Poland and the Netherlands, and is currently building one of the most modern biosimilar drug production plants in Duchnice near Warsaw, offering a fully integrated chain of biotechnological services. The group creates cell lines, optimizes manufacturing processes, ensures production of biosimilar drugs on a commercial scale for its own products and will provide contract manufacturing services for international industry partners.

Polpharma Biologics: www.polpharmabiologics.com

Media contact:

Marta Gliszczyńska

e-mail: marta.gliszczyńska@big-picture.pl

tel.: 666 032 999